Opaleye Management Amends Eton Pharma Stake (Amendment No. 6)

TL;DR

**Opaleye Management just updated their Eton Pharma stake, signaling a potential shift in institutional sentiment.**

AI Summary

Opaleye Management Inc., an investment firm based in Boston, MA, filed an amended SC 13G/A on February 9, 2024, indicating a change in their beneficial ownership of Eton Pharmaceuticals, Inc. common stock as of December 31, 2023. This filing, Amendment No. 6, updates previous disclosures regarding their stake in the pharmaceutical company. For investors, this matters because significant changes in institutional ownership can signal shifts in confidence or strategy regarding Eton Pharmaceuticals' future prospects.

Why It Matters

Changes in institutional ownership can influence stock price and reflect a major investor's updated view on the company's value or future performance.

Risk Assessment

Risk Level: low — This filing is a routine update on institutional ownership and does not inherently indicate a high-risk event for the company.

Analyst Insight

An investor should monitor subsequent 13G/A filings from Opaleye Management Inc. to track their evolving position in Eton Pharmaceuticals, Inc., as significant changes could indicate a shift in their investment thesis.

Key Numbers

• 0001493152-24-005666 — Accession Number (unique identifier for this specific SEC filing)
• 20240209 — Filed As Of Date (the date this amendment was filed with the SEC)
• 12/31/2023 — Date of Event (the date of the event that required this filing)
• 6 — Amendment Number (indicates this is the sixth amendment to the original filing)
• 005-90726 — SEC File Number (the SEC file number for Eton Pharmaceuticals, Inc.)

Key Players & Entities

• Opaleye Management Inc. (company) — the reporting person and investment firm
• Eton Pharmaceuticals, Inc. (company) — the subject company whose stock is being reported
• James Silverman (person) — person authorized to receive notices for Opaleye Management Inc.
• Boston, MA (location) — business address of Opaleye Management Inc.
• Deer Park, IL (location) — business address of Eton Pharmaceuticals, Inc.

Forward-Looking Statements

• Opaleye Management Inc. will continue to be a significant institutional holder of Eton Pharmaceuticals, Inc. stock. (Opaleye Management Inc.) — medium confidence, target: 12/31/2024

FAQ

Key Financial Figures

• $0.001 — me of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securiti

Filing Documents

• formsc13ga.htm (SC 13G/A) — 80KB
• 0001493152-24-005666.txt ( ) — 82KB

From the Filing

SC 13G/A 1 formsc13ga.htm UNITED SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. __6______)* ETON PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 29772L108 (CUSIP Number) James Silverman, One Boston Place, 26 th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications) 12/31/2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is filed: Rule 13d-1(b) Rule 13d-1(c) Rule 13d-1(d) * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page. The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 000000000 13G/A Page 2 of 5 Pages 1. NAMES OF REPORTING PERSONS Opaleye Management, Inc. I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY) 20-5648796 2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see instructions) (a) (b) 3. SEC USE ONLY 4. CITIZENSHIP OR PLACE OF ORGANIZATION Massachusetts NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH 5. SOLE VOTING POWER 0 6. SHARED VOTING POWER 2,524,887 7. SOLE DISPOSITIVE POWER 0 8. SHARED DISPOSITIVE POWER 2,524,887 9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 2,524,887 10. CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions) 11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 9.84% 12. TYPE OF REPORTING PERSON (see instructions) CO * Based upon 25,658,396 shares of common stock issued and outstanding on November 3, 2023 as reported by the Issuer on its registration exercise or conversion of outstanding securities of the Issuer. CUSIP No. 000000000 13G/A Page 3 of 5 Pages Item 1. (a) Name of Issuer: Eton Pharmaceuticals, Inc. (the “Company”). (b) Address of Issuer’s Principal Executive Offices: 21925 W. Field Parkway, Suite 235, Deer Park, Illinois 60010 Item 2. (a) Name of Person Filing Opaleye, L.P. (b) Address of the Principal Office or, if none, residence One Boston Place, 26 th Floor, Boston, MA 02108 (c) Citizenship is set forth in Row 4 of the cover page for each Reporting Person and is incorporated herein by reference for each such Reporting Person. (d) Title of Class of Securities Common Stock, $0.001 par value per share (e) CUSIP Number 29772L108 Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a: (a) Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o). (b) Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c). (c) Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c). (d) Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8). (e) An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G); (h) A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813); (i) A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3); (j) Group, in accordance with §240.13d-1(b)(1)(ii)(J). CUSIP No. 000000000 13G/A Page 4 of 5 Pages Item 4. Ownership. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned: 2,524,887 (b) Percent of class: 9.84% (c) Number of shares as to which the person has: 2,524,887 (i) Sole power to vote or to direct the vote 0 (ii) Shared power to vote or to direct the vote 2,524,887 (iii) Sole power to dispose or to direct the disposition of 0 (iv) Shared power to dispose or to direct the disposition of 2,524,887 * Based upon 25,658,396 shares of common stock issued and outstanding on November 3, 2023 as reported by the Issuer on its registration exercise or conversion of outstanding securities of the Issuer. Instruction . Fo

View Full Filing

View this SC 13G/A filing on SEC EDGAR